Beam Therapeutics BEAM Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: Beam Therapeutics’s 10-Q, filed November 8, 2023, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's finance lease liabilities?
- Beam Therapeutics (BEAM) reported finance lease liabilities of $304K in Q3 2023.
- How has Beam Therapeutics's finance lease liabilities changed year-over-year?
- Beam Therapeutics's finance lease liabilities decreased by 78.1% year-over-year, from $1.39M to $304K.
- What is the long-term trend for Beam Therapeutics's finance lease liabilities?
- Over 2 years (2020 to 2022), Beam Therapeutics's finance lease liabilities has grown at a -53.3% compound annual growth rate (CAGR), from $5.29M to $1.15M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.